Convidecia™ Phase III results published in The Lancet – QNT Press Release


  • The effective rate against serious diseases for people aged 18 and over 14 days after vaccination is 96.0%.
  • Single-dose vaccines are approved in at least 10 markets, including China, Mexico, Ecuador, Chile, Argentina, Hungary, Kyrgyzstan, Pakistan, Indonesia and Malaysia.

Tianjing, China, December 24, 2021 /PRNewswire/ – CanSino Biologics Inc. (“CanSinoBIO”) (SSE: 688185, HKEX: 06185) today announced “The Lancet”[1] Announced the results of a phase III clinical trial on the safety and effectiveness of its recombinant new coronavirus vaccine (adenovirus type 5 vector) (“Ad5-nCoV”, trade name: Convidecia™). The analysis results show that a single dose of Convidecia™ is effective and safe. The effectiveness of preventing severe COVID-19 disease is 96.0%. The overall effectiveness of healthy adults 18 years of age and above within 14 days after vaccination is 63.7%. There is no report. Serious adverse events related to vaccines.

“We are very pleased that the results of our phase III trial were fully disclosed and published in the Lancet, one of the most prestigious peer-reviewed medical journals in the world. This represents another milestone and further proves our single dose The strong protection provided by the vaccine has been approved in at least 10 markets on multiple continents. CanSinoBIO remains committed to the mission of providing affordable, timely and large-scale immunization protection for the global population, and will continue to cooperate with the public and private sectors Of partners work together to improve vaccine access and allow more people to benefit from our…

The full story can be found on


Source link

Recommended For You

About the Author: News Center